Literature DB >> 1536832

Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.

T C Lee1, B A Sullenger, H F Gallardo, G E Ungers, E Gilboa.   

Abstract

Overexpression of sequences corresponding to the major Rev-binding site in the Rev response element of human immunodeficiency virus type 1 (HIV-1) (RRE decoys) was used to render cells resistant to HIV-1 replication. This was accomplished by the use of a chimeric tRNA-RRE transcription unit in a double-copy murine retroviral vector to express high levels of HIV-1 RRE-containing transcripts in CEM SS cells. Replication of HIV-1 was inhibited more than 90% in cells expressing chimeric tRNA-RRE transcripts, as determined by in situ immunofluorescence analysis and a p24 antigen ELISA test. Analysis of RNA from HIV-1-infected cells suggests that expression of RRE-containing sequences in CEM SS cells inhibits HIV-1 replication by interfering with Rev function, presumably by competing for Rev binding to its physiological target. The use of a subfragment of RRE as decoy RNA reduces the likelihood that essential cellular factors will be sequestered in cells expressing the decoy RNA. Thus, use of RRE-based decoy RNA to inhibit HIV-1 replication may represent a safer alternative to the use of TAR decoy RNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1536832

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  31 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  HIV-1 RRE RNA acts as an RNA silencing suppressor by competing with TRBP-bound siRNAs.

Authors:  Sylvanne M Daniels; Lucile Sinck; Natalie J Ward; Carlos E Melendez-Peña; Robert J Scarborough; Ibrahim Azar; Elodie Rance; Aïcha Daher; Ka-Ming Pang; John J Rossi; Anne Gatignol
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

4.  Selective optimization of the Rev-binding element of HIV-1.

Authors:  L Giver; D Bartel; M Zapp; A Pawul; M Green; A D Ellington
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

Review 5.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Inhibition of hepatitis C virus replication by single-stranded RNA structural mimics.

Authors:  Robert Smolic; Martina Smolic; John H Andorfer; Catherine H Wu; Robert M Smith; George Y Wu
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

7.  Gene therapy for HIV infections: Intracellular immunization.

Authors:  A Piché
Journal:  Can J Infect Dis       Date:  1999-07

8.  A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1.

Authors:  O Yamada; G Kraus; L Luznik; M Yu; F Wong-Staal
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

9.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

10.  Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication.

Authors:  Deidra Shuck-Lee; Fei Fei Chen; Ryan Willard; Sharmila Raman; Roger Ptak; Marie-Louise Hammarskjold; David Rekosh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.